Search research articles
Contact Us
Filters
Showing results (1-10 of 82) with videos related to
Page
of 9
Sort By:
The New England Journal of Medicine
|
December 3, 2025
Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial
Marcel H A Muskiet, Mark M Smits
The Lancet. Diabetes & Endocrinology
|
July 19, 2025
Beyond a singular focus on GLP-1: why we need a new nomenclature now
Marcel H A Muskiet, Mark M Smits
Lancet (London, England)
|
June 7, 2026
Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care
Daniël H van Raalte, Marcel H A Muskiet
The American Journal of Clinical Nutrition
|
September 22, 2012
Should dietary SFA be exchanged for linoleic acid?
Frits A J Muskiet, Marcel H A Muskiet
Kidney International
|
January 29, 2021
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F E Mann, Marcel H A Muskiet
Advances in Therapy
|
October 25, 2019
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneilly
Advances in Therapy
|
December 25, 2019
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneilly
The New England Journal of Medicine
|
June 9, 2016
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits
Circulation
|
August 12, 2015
Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"
Marcel H A Muskiet, Lennart Tonneijck, Daniël H van Raalte
The New England Journal of Medicine
|
December 1, 2017
Liraglutide and Renal Outcomes in Type 2 Diabetes
Lennart Tonneijck, Daniël H van Raalte, Marcel H A Muskiet
Page
of 9
Search research articles
Search
Showing results (1-10 of 82) with videos related to
Sort By:
Page
of 9
The New England Journal of Medicine
|
December 3, 2025
Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial
Marcel H A Muskiet, Mark M Smits
The Lancet. Diabetes & Endocrinology
|
July 19, 2025
Beyond a singular focus on GLP-1: why we need a new nomenclature now
Marcel H A Muskiet, Mark M Smits
Lancet (London, England)
|
June 7, 2026
Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care
Daniël H van Raalte, Marcel H A Muskiet
The American Journal of Clinical Nutrition
|
September 22, 2012
Should dietary SFA be exchanged for linoleic acid?
Frits A J Muskiet, Marcel H A Muskiet
Kidney International
|
January 29, 2021
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F E Mann, Marcel H A Muskiet
Advances in Therapy
|
October 25, 2019
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneilly
Advances in Therapy
|
December 25, 2019
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
Yehuda Handelsman, Marcel H A Muskiet, Graydon S Meneilly
The New England Journal of Medicine
|
June 9, 2016
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits
Circulation
|
August 12, 2015
Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"
Marcel H A Muskiet, Lennart Tonneijck, Daniël H van Raalte
The New England Journal of Medicine
|
December 1, 2017
Liraglutide and Renal Outcomes in Type 2 Diabetes
Lennart Tonneijck, Daniël H van Raalte, Marcel H A Muskiet
Page
of 9